Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
#ENDSARS: Diasporas urge FG to employ strategic measures
03:14am, Friday, 23'rd Oct 2020
By Fortune Abang Abuja, Oct. 22, 2020 The African Diaspora Congress (ADC) on Thursday urged the Federal Government to employ strategic measures aimed at protecting unarmed protesters to ensure safe…
Agree Realty: High-Quality Net Lease REIT Playing Offense And Defense At The Same Time (NYSE:ADC)
04:47pm, Thursday, 22'nd Oct 2020
ADC has been playing some serious offense this year, acquiring almost $1 billion of properties. At the same time, it has also been playing some strong defense by focusing on investment grade, omnichan
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results
12:00am, Thursday, 22'nd Oct 2020
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results
Arden Trust Co Sells 2,736 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)
06:34am, Monday, 19'th Oct 2020
Arden Trust Co reduced its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN) by 12.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 19,589 shares of the biotech
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
ADC Therapeutics (NYSE:ADCT) PT Lowered to $52.00
04:32am, Wednesday, 14'th Oct 2020
ADC Therapeutics (NYSE:ADCT) had its price objective lowered by Morgan Stanley from $53.00 to $52.00 in a report issued on Tuesday morning, Benzinga reports. The firm currently has an overweight ratin
Iksuda Therapeutics Enters License Agreement With University of Goettingen to Develop a New Generation of Antibody Drug Conjugates
12:00am, Tuesday, 13'th Oct 2020
Iksuda Therapeutics (Iksuda), the developer of enhanced, new-generation of Antibody Drug Conjugates (ADCs), today announces it has executed its option
ADC Therapeutics meldet vollumfängliche Inanspruchnahme der den Underwritern eingeräumten Option für den Kauf zusätzlicher Stammaktien
12:00am, Saturday, 10'th Oct 2020
ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und V
ImmunoGen, Inc. (NASDAQ:IMGN) Position Boosted by Principal Financial Group Inc.
07:33am, Friday, 09'th Oct 2020
Principal Financial Group Inc. increased its holdings in ImmunoGen, Inc. (NASDAQ:IMGN) by 334.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commiss
ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
12:00am, Friday, 09'th Oct 2020
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of hig
ImmunoGen Soars 14% On FDA Breakthrough Designation For Blood Cancer Therapy
09:48am, Tuesday, 06'th Oct 2020
Shares of ImmunoGen spiked 14.2% on Monday after the biotechnology company said that the U.S. Food and Drug Administration (FDA) granted breakthrough
ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
11,900 Shares in ImmunoGen, Inc. (NASDAQ:IMGN) Acquired by Engineers Gate Manager LP
06:28am, Friday, 02'nd Oct 2020
Engineers Gate Manager LP acquired a new position in shares of ImmunoGen, Inc. (NASDAQ:IMGN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange
Agenus Vs. Seattle Genetics Cervical Cancer Clinical Trial Results (NASDAQ:AGEN)
07:30am, Wednesday, 30'th Sep 2020
Agenus's balstilimab and zalifrelimab nears FDA submission for cervical cancer. Seattle Genetics presented tisotumab vedotin cervical cancer data at ESMO.
